Since TEVs, regardless of their derivation from NTRK1- or NTRK2-expressing cells, display obstructing effects on CD4+ CAR T cells in vitro, it should be tested whether CD8+ CAR T cells are a better suited for cell-based neuroblastoma immunotherapy. The gene discussed is NTRK2; the disease is neuroblastoma.